Tag Archives: Shire

Shire Takeover "Could Save AbbVie $8 Billion Tax on Humira over Next 15 Years"

AbbVie’s recent $54 billion acquisition of Shire and subsequent relocation to Ireland will mean substantial tax savings for the US pharmaceutical giant, according to analysts at research and consulting firm GlobalData.
Posted in Deals, Europe, Global, Strategy | Also tagged , , , | Leave a comment

The Rx Firm Tax Exodus: Is Something Wrong with the U.S. System?

As I read the latest reports of yet another big US Rx firm, this time AbbVie, trying to pull off a “tax inversion” takeover of the Irish-based Shire, I couldn’t help but wonder, what the heck is going on here? Right now, it feels like most major US corporations, especially pharmas, are literally running away […]
Posted in Deals, Europe, Global, Guest Blog, Legal, Op-Ed, Strategy | Also tagged , , , , , | Leave a comment

Suffer Little Children? To Medicate or Not to Medicate Toddlers

When Audre McDonald accepted her sixth Tony Award (theater’s version of the Academy Awards) this month in New York City, and broadcast live on national television, she thanked her parents “for their unwillingness to put her on stimulant medication, which she believed led to her stunning success in musical theater.” In the aftermath, her comments […]
Posted in FDA, Global, healthcare | Also tagged , , , , | Leave a comment

Promotional Review Committees: Shire Sets the Standard on Achieving High Performing Teams

by Arthur Lazarus What does it take for internal Promotional Review Committees to function at their best and avoid costly mistakes to the company? A leading industry practitioner offers 15 tips for high performing teams. Arthur Lazarus, MD, MBA, Shire Pharmaceuticals 1. Find a common voice. Given the diverse training and background of individuals who […]
Posted in compliance, E-Media, Legal, Marketing, Strategy | Also tagged , , , , , , | 2 Comments

Feds Threaten to Pull ProAmatine for Lack of Postmarket Data (Updated 8/18)

Image via Wikipedia FDA on Monday announced that it was looking to withdraw approval for the low-blood-pressure treatment midodrine hydrochloride because the companies manufacturing the drug failed to provide data from post-approval studies. The kicker: The drug was approved 14 years ago. FDA gave midodrine hydrochloride—branded by Shire as ProAmatine and produced by a half-dozen […]
Posted in FDA | Also tagged , , , , , , , | 1 Comment
  • Categories

  • Meta